| Name | Title | Contact Details |
|---|
Commonwealth Diagnostics International (CDI), Inc., was founded on the principle that preventative healthcare, including early detection and diagnosis of disease, results in expedited treatment, better patient outcomes, and robust cost savings for the healthcare delivery system. Operating out of a newly constructed laboratory in Salem, MA, CDI is an international diagnostic service provider specializing in innovative diagnostic products that assist physicians and patients with the diagnosis and management of some of the world`s most common sources of digestive distress and functional gastrointestinal disorders, including: hydrogen (H2)/methane (CH4) breath testing for Small Intestinal Bacterial Overgrowth (SIBO) and carbohydrate malabsorption, IBSchek™ for IBS-D/M; and AbStats™, an easy-to-use, noninvasive, and reliable digestive telemetry and sensory system. CDI focuses on creating customized operational solutions to diagnostic technologies that drive accessibility and simplicity in lieu of outdated, expensive, invasive, and inaccessible diagnostic modalities. CDI`s entire portfolio of tests can be utilized either at home or with one simple trip to the physician. CDI`s laboratory specializes in customized gas chromatography, ELISA, and isotope-ratio mass spectrometry solutions.
Caresyntax is on a mission to make surgery smarter and safer. Our enterprise-grade digital surgery platform delivers actionable insights to improve patient outcomes by using proprietary software and AI to analyze large volumes of video, audio, images, device data, clinical, and operational data in and around the OR.
DispatchHealth is redefining healthcare delivery through the most advanced on-demand, in-home healthcare model in the country. Our board-certified medical teams can treat common to complex injuries and illnesses in the comfort of your home.
URAC is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
AVEO Oncology (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering and developing targeted therapies designed to provide substantial impact in patients` lives with clear unmet medical needs. AVEO`s proprietary Human Response PlatformTM provides the company unique insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics.